Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults

Vaccine

Volumn 19, Issue 2-3, 2000, Pages 217-226

  Boyce, Thomas G ^a   Hsu, Henry H ^b   Sannella, Edith C ^c   Coleman Dockery, Shanita D ^c   Baylis, Elizabeth ^d   Zhu, Yuwei ^c   Barchfeld, Gail ^b   Difrancesco, Anita ^b   Paranandi, Mallikharjun ^b   Culley, Barbara ^c   Neuzil, Kathleen M ^e   Wright, Peter F ^c  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Div Pediat Infect Dis Dept P   (United States)

^d VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Intranasal influenza vaccine; MF59; Mucosal immunity; Vaccine adjuvants

Indexed keywords

AGRIPPAL S1; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; INFLUENZA VACCINATION; MALE; MUCOSAL IMMUNITY; NORMAL HUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION;

EID: 0034666727     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00171-7     Document Type: Article

References (43)

1. Glezen W.P. Emerging infections; pandemic influenza. Epidemiol. Rev. 18:1996;64-76.
2. Simonsen L., Clarke M.J., Williamson G.D., Stroup D.F., Arden N.H., Schonberger L.B. The impact of influenza epidemics on mortality: introducing a severity index. Am. J. Public Health. 87:1997;1944-1950.
3. Edwards K.M., Dupont W.D., Westrich M.K., Plummer W.D. Jr., Palmer P.S., Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J. Infect. Dis. 169:1994;68-76.
4. Sugaya N., Nerome K., Ishida M., Matsumoto M., Mitamura K., Nirasawa M. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type. B. Jama. 272:1994;1122-1126.
5. Keitel W.A., Cate T.R., Couch R.B. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am. J. Epidemiol. 127:1988;353-364.
6. Kohn M.A., Farley T.A., Sundin D., Tapia R., McFarland L.M., Arden N.H. Three summertime outbreaks of influenza type A. J. Infect. Dis. 172:1995;246-249.
7. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 24:1986;157-160.
8. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., Bernstein D.I., Hayden F.G., Kotloff K., Zangwill K., Iacuzio D., Wolff M. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338:1998;1405-1412.
9. Boyce T.G., Gruber W.C., Coleman-Dockery S.D., Sannella E.C., Reed G.W., Wolff M., Wright P.F. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine. 18:1999;82-88.
10. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest, P., Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6:1995;277-296.
11. Graham B.S., Keefer M.C., McElrath M.J., Gorse G.J., Schwartz D.H., Weinhold K., Matthews T.J., Esterlitz J.R., Sinangil F., Fast P.E. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern. Med. 125:1996;270-279.
12. Keefer M.C., Graham B.S., McElrath M.J., Matthews T.J., Stablein D.M., Corey L., Wright P.F., Lawrence D., Fast P.E., Weinhold K., Hsieh R.H., Chernoff D., Dekker C., Dolin R. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP- PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses. 12:1996;683-693.
13. Kahn J.O., Sinangil F., Baenziger J., Murcar N., Wynne D., Coleman R.L., Steimer K.S., Dekker C.L., Chernoff D. Clinical and immunologic responses to human immunodeficiency virus (HIV) type ISF2 gp 120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis. 170:1994;1288-1291.
14. Corey L., Langenberg A.G., Ashley R., Sekulovich R.E., Izu A.E., Douglas J.M. Jr., Handsfield H.H., Warren T., Marr L., Tyring S., DiCarlo R., Adimora A.A., Leone P., Dekker C.L., Burke R.L., Leong W.P., Straus S.E. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. Jama. 282:1999;331-340.
15. Cataldo D.M., Van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine. 15:1997;1710-1715.
16. Ott G., Barchfeld G.L., Van Nest, G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine. 13:1995;1557-1562.
17. Menego T., Baldo V., Boneelo C., Dalla Costa, D., Di Tommaso, A., Trivello R. Influenza vaccines: Antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur. J. Epidem. 15:1999;573-576.
18. Barchfeld G.L., Hessler A.L., Chen M., Pizza M., Rappuoli R., Van Nest G.A. The adjuvants MF59 and LT-K63 enhance and mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine. 17:1999;695-704.
19. Murphy B.R., Webster R.G. Orthomyxoviruses. Field B.N, Knipe D.M, Howley PM. Field's Virology. 3rd ed. 1996;1397-1446 Lippincott-Raven, Philadelphia.
20. Hierholzer J.C., Suggs M.T., Hall E.C. Standardized viral hemagglutination and hemagglutination-inhibition tests. II. Description and statistical evaluation. Appl. Microbiol. 18:1969;824-833.
21. Hierholzer J.C., Suggs M.T. Standardized viral hemagglutination and hemagglutination-inhibition tests. I. Standardization of erythrocyte suspensions. Appl. Microbiol. 18:1969;816-823.
22. Thompson J., Pham D.M., Werkaven J.A., Sannella E., Ikizler M., Wright P.F. Optimal collection and assay of upper respiratory specimens for determination of mucosal immune responses to influenza. Brown L.E., Hampson A.W, Webster R.G. Options for the Control of Influenza III. 1996;263-270 Elsevier, Amsterdam.
23. Douglas R.G. Jr. Prophylaxis and treatment of influenza. N. Engl. J. Med. 322:1990;443-450.
24. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine. 17:(Suppl. 1):1999;S3-10.
25. Ada G.L., Jones P.D. The immune response to influenza infection. Curr. Topics Microbiol. Immunol. 128:1986;3-54.
26. Powers D.C., Fries L.F., Murphy B.R., Thumar B., Clements M.L. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J. Clin. Microbiol. 29:1991;498-505.
27. Treanor J.J., Mattison H.R., Dumyati G., Yinnon A., Erb S., O'Brien D., Dolin R., Betts R.F. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann. Intern. Med. 117:1992;625-633.
28. Quilligan J.J. Jr., Francis T.Jr. Serological response to intranasal administration of inactive influenza virus in children. J. Clin. Invest. 26:1947;1079-1087.
29. Waldman R.H., Wood S.H., Torres E.J., Small P.A. Jr. Influenza antibody response following aerosal administration of inactivated virus. Am. J. Epidemiol. 91:1970;574-585.
30. Kasel J.A., Hume E.B., Fulk R.V., Togo Y., Huber M., Hornick R.B. Antibody responses in nasal secretions and serum of elderly persons following local or parenteral administration of inactivated influenza virus vaccine. J. Immunol. 102:1969;555-562.
31. Waldman R.H., Mann J.J., Small P.A. Jr. Immunization against influenza. Prevention of illness in man by aerosolized inactivated vaccine. Jama. 207:1969;520-524.
32. Gupta R.K., Griffin P.Jr., Chang A.C., Rivera R., Anderson R., Rost B., Cecchini D., Nicholson M., Siber G. The role of adjuvants and delivery systems in modulation of immune response to vaccines. Cohen S., Shafferman A. Novel strategies in design and production of vaccines. 1996;105-113 Plenum Press, New York.
33. Couch R.B., Keitel W.A., Cate T.R., Quarles J.A., Taber L.A., Glezen W.P. Prevention of influenza virus infections by current inactivated influenza virus vaccines. Brown L.E., Hampson A.W., Webster R.G. Options for the Control of Influenza III. 1996;97-106 Elsevier Science.
34. Mostow S.R., Schoenbaum S.C., Dowdle W.R., Coleman M.T., Kaye H.S. Inactivated vaccines. 1. volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation. Postgrad. Med. J. 49:1973;152-158.
35. Wenzel R.P., Hendley J.O., Sande M.A., Gwaltney J.M. Revised (1972-1973) bivalent influenza vaccine serum and nasal antibody responses to parenteral vaccination. Jama. 226:1973;435-438.
36. Fulk R.V., Fedson D.S., Huber M.A., Fitzpatrick J.R., Howar B.F., Kasel J.A. Antibody responses in children and elderly persons following local or parenteral administration of an inactivated influenza virus vaccine, A2- Hong Kong-68 variant. J. Immunol. 102:1969;1102-1105.
37. Mann J.J., Waldman R.H., Togo Y., Heiner G.G., Dawkins A.T., Kasel J.A. Antibody response in respiratory secretions of volunteers given live and dead influenza virus. J. Immunol. 100:1968;726-735.
38. Gorse G.J., Otto E.E., Powers D.C., Chambers G.W., Eickhoff C.S., Newman F.K. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J. Infect. Dis. 173:1996;285-290.
39. Glezen W.P. Influenza control - unfinished business. Jama. 281:1999;944-945.
40. Wright P.F., Murphy B.R., Kervina M., Lawrence E.M., Phelen M.A., Karzon D.T. Secretory immunologic response after intranasal inactivated influenza. A virus vaccination: evidence for immunoglobulin A memory. Infect. Immunol. 40:1983;1092-1095.
41. Hashigucci K., Ogawa H., Ishidate T., Yamashita R., Kamiya H., Watanabe K., Hattori N., Sato T., Suzuki Y., Nagamine T., Aizawa C., Tamura S., Kurata T., Oya A. Antibody response in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine. 14:1996;113-119.
42. Tamura S., Kurata H., Nagamine T., Aizawa C., Kurata T. Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit. Vaccine. 7:1989;314-320.
43. Pizza M., Domenighini M., Hol W., Giannelli V., Fontana M.R., Giuliani M.M., Magagnoli C., Peppoloni S., Manetti R., Rappuoli R. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol. Microbiol. 14:1994;51-60.